Back to Journals » Drug Design, Development and Therapy » Volume 13
Review
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
11,853 | Dovepress* | 7,975+ | 1,576 | 9,551 | |
PubMed Central* | 3,878 | 852 | 4,730 | ||
Totals | 11,853 | 2,428 | 14,281 | ||
*Since 8 February 2019 |
View citations on PubMed Central and Google Scholar